Novartis has confirmed nine instances—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma® (onasemnogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results